The clinical landscape of acne is often complicated by long-standing misconceptions that can hinder effective treatment. One of the most persistent myths is that microneedling over active acne will spread bacteria across the face; however, this is not how the condition works.

Dr Christie-Schwarz clarified that acne is not passed from person to person, nor is it directly caused by eating certain foods. Furthermore, common practices like over-cleansing or using harsh astringents to "dry out" a pimple can actually deactivate regulatory enzymes. This leads to dehydration, which contributes to clogging and congestion rather than resolving the issue.

For medical practitioners, understanding that sebum is not inherently "evil" but a vital component that has protected the skin's barrier for millions of years is the first step toward a more effective solution.

Successful long-term acne management requires a professional to address three key pathophysiological triggers simultaneously.

Sebum production is dictated by hormones, specifically testosterone and dehydrotestosterone. When an over-conversion occurs, sebum thickens to a consistency similar to room-temperature butter, leading it to stick to dirt and dead skin cells. Dp Dermaceuticals™ mesoglides to be used during microneedling, like MG-CLR™, help rebalance sebum production and prevent future congestion.

Retention hyperkeratosis is the medical term for the clogging and congestion that begins at the opening of the follicle and extends downward. This process is regulated by Keratinocyte Growth Factor (KGF) and enzymes activated by water. Dermapen 4® treatments help rebalance and activate KGF, enabling a cleaner and more efficient keratinisation process.

The bacterium associated with acne, Cutibacterium acnes (C. acnes), is anaerobic, meaning it thrives in environments without oxygen. When a follicle becomes clogged and oxygen-deprived, these bacteria move in and trigger inflammation. By creating 1,920 puncture channels per second, the Dermapen 4® delivers unprecedented oxygenation, asphyxiating the bacteria.

The Webinar highlighted several innovative data points that empower clinics to deliver better patient results:

• Evidence-based efficacy: A study in India involving more than 50 patients showed a 54% reduction in acne severity after four procedures with Dermapen 4® and Dp Dermaceuticals MG-CLR™.

• Synergy of Solutions™: Combining mechanical regeneration with the Dermapen 4® and chemical agents such as Dp Dermaceuticals ÜBER PRO™ and MG-CLR provides a multidimensional approach. ÜBER PRO acts as an anabolic peel that helps break down thickened sebum without the typical shedding or frosting associated with traditional peels.

• Preventative care: Targeting active acne with these protocols prevents the activation of lipase enzymes that attack the follicular wall, thereby preventing the formation of permanent boxcar or ice-pick scars.

• Patient comfort: These advanced protocols are well tolerated and do not require a topical anaesthetic, allowing for quick, efficient in-clinic procedures.